Exalenz Bioscience Ltd. appointed Roy Golan CPA, LLM as President and Chief Financial Officer. Mr. Golan will report to the CEO, Raffi Werner. Mr. Golan, has more than 18 years of experience in the healthcare and software industries, and has held executive finance positions in several cutting-edge growth private and public companies including the Parkinson's disease therapeutic and gastroenterology screening arenas.

Most recently, Mr. Golan was Chief Financial Officer at NeuroDerm Ltd. Subsequent to joining NeuroDerm in January 2014, he played a critical role in planning and executing the company's initial public offering in the U.S. on Nasdaq in November 2014.